Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Recruiting now · Phase 1/Phase 2
Conditions studied: Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
In brief
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
Key facts
- Study ID
- NCT07145255
- Run by
- MBrace Therapeutics
- People needed
- 150
- Starts
- 2025-09-03
- Expected to finish
- 2029-12-30
- Last updated by the study team
- 2026-02-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States (enrolling)
- START, Midwest — Grand Rapids, Michigan, United States (enrolling)
- START, Astera — East Brunswick, New Jersey, United States (enrolling)
- NEXT, Dallas — Irving, Texas, United States (enrolling)
- START San Antonio — San Antonio, Texas, United States (enrolling)
- START, Mountain Region — West Valley City, Utah, United States (enrolling)
- NEXT, Virginia — Fairfax, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.